Chimeric Therapeutics Limited (ASX:CHM)
Australia · Delayed Price · Currency is AUD 0.0050
+0.0010 (25.00%)
Sep 25, 2026, 4:10 PM AEST
Chimeric Therapeutics Balance Sheet
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Cash & Equivalents | 0.8 | 5.76 | 3.05 | 2.36 | 18.38 |
Cash & Short-Term Investments | 0.8 | 5.76 | 3.05 | 2.36 | 18.38 |
Cash Growth | -86.10% | 88.58% | 29.22% | -87.15% | -17.98% |
Accounts Receivable | - | 4.55 | 0.09 | 6.66 | 0.04 |
Other Receivables | 0.03 | - | - | - | 2.62 |
Receivables | 0.03 | 4.55 | 0.09 | 6.66 | 2.66 |
Other Current Assets | 0.19 | 0.22 | 0.08 | 0.33 | 0.13 |
Total Current Assets | 1.02 | 10.53 | 3.22 | 9.35 | 21.17 |
Property, Plant & Equipment | - | - | 0 | 0.01 | 0.02 |
Long-Term Investments | - | - | 0.04 | 0.04 | 0.04 |
Other Intangible Assets | 0.25 | 11.04 | 12.01 | 12.98 | 13.65 |
Total Assets | 1.28 | 21.57 | 15.27 | 22.38 | 34.88 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Accounts Payable | 5.4 | 6.57 | 3.2 | 7.41 | 4.7 |
Accrued Expenses | 0.7 | 1.75 | 3.24 | 3.77 | 1.83 |
Short-Term Debt | 0.66 | - | - | - | - |
Other Current Liabilities | 2.13 | 6.3 | 3.66 | 3.52 | 2.49 |
Total Current Liabilities | 8.89 | 14.61 | 10.1 | 14.69 | 9.02 |
Pension & Post-Retirement Benefits | 0 | 0 | - | - | - |
Other Long-Term Liabilities | 0.11 | 4.98 | 2.71 | 2.02 | 0.15 |
Total Liabilities | 9 | 19.6 | 12.8 | 16.71 | 9.17 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Common Stock | 80.41 | 70.16 | 63.51 | 53.93 | 51.81 |
Retained Earnings | -94.57 | -76.33 | -66.56 | -56.78 | -30.86 |
Comprehensive Income & Other | 6.43 | 8.15 | 5.52 | 8.51 | 4.76 |
Shareholders' Equity | -7.72 | 1.97 | 2.47 | 5.66 | 25.71 |
Total Liabilities & Equity | 1.28 | 21.57 | 15.27 | 22.38 | 34.88 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Total Debt | 0.66 | - | - | - | - |
Net Cash (Debt) | 0.14 | 5.76 | 3.05 | 2.36 | 18.38 |
Net Cash Growth | -97.59% | 88.58% | 29.22% | -87.15% | -17.98% |
Net Cash Per Share | 0.00 | 0.43 | 0.44 | 0.55 | 5.11 |
Filing Date Shares Outstanding | 54.73 | 32.55 | 9.05 | 5.29 | 4.25 |
Total Common Shares Outstanding | 54.73 | 20.15 | 8.76 | 5.07 | 4.25 |
Working Capital | -7.86 | -4.09 | -6.87 | -5.34 | 12.15 |
Book Value Per Share | -0.14 | 0.10 | 0.28 | 1.12 | 6.04 |
Tangible Book Value | -7.98 | -9.07 | -9.54 | -7.32 | 12.05 |
Tangible Book Value Per Share | -0.15 | -0.45 | -1.09 | -1.44 | 2.83 |